Previous Article | Next Article 
Journal of Virology, December 2000, p. 11522-11530, Vol. 74, No. 24
0022-538X/00/$04.00+0
Correct Integration of Model Substrates by
Ty1 Integrase
Sharon P.
Moore* and
David J.
Garfinkel
Gene Regulation and Chromosome Biology
Laboratory, National Cancer Institute-Frederick Cancer Research
and Development Center, National Institutes of Health, Frederick,
Maryland 21702-1201
Received 11 July 2000/Accepted 26 September 2000
 |
ABSTRACT |
The retrovirus-like mobile genetic element of Saccharomyces
cerevisiae, Ty1, transposes to new genomic
locations via the element-encoded integrase (IN). Here we report
that purified recombinant IN catalyzed correct integration of a linear
DNA into a supercoiled target plasmid. Ty1 virus-like particles (VLPs)
integrated donor DNA more efficiently than IN. VLP and IN-mediated
insertions occurred at random sites in the target. Mg2+ was
preferred over Mn2+ for correct integration, and neither
cation enhanced nonspecific nuclease activity of IN. Products
consistent with correct integration events were also obtained by
Southern analysis. Recombinant IN and VLPs utilized many, but not all,
linear donor fragments containing non-Ty1 ends, including a U3 mutation
which has been shown to be defective for transposition in vivo.
Together, our results suggest that IN is sufficient for Ty1 integration
in vitro and IN interacts with exogenous donors less stringently than
with endogenous elements.
 |
INTRODUCTION |
Ty1 is a retrotransposon of
Saccharomyces cerevisiae which is structurally and
functionally similar to retroviruses (for review, see references
3 and 18). Transcription of a
genomic element results in the formation of intracellular
virus-like particles (VLPs) which contain the element-encoded
catalytic enzymes required for the process of transposition: protease,
reverse transcriptase, and integrase (IN) as well as Ty1 RNA and a
cellular tRNAMet required to prime reverse transcription.
The resulting full-length cDNA copy is correctly inserted into a new
genomic location by IN-mediated strand transfer. Correct Ty1
integration events are characterized by a 5-bp target site duplication
(TSD) without rearrangement or loss of sequence adjacent to the
insertion site and by the coupled joining of both termini of the
element to a single insertion site (concerted integration).
Both Ty1 VLPs and recombinant IN are active in a physical assay which
monitors the insertion of a radioactively labeled long terminal repeat
(LTR)-based oligoduplex into an identical target molecule
(29). Although this assay demonstrates strand exchange activity of both recombinant IN and VLP-associated IN, it bears limited
similarity to transposition in vivo. A transposition assay has been
developed which detects the integration of supF-marked Ty1
elements into bacteriophage lambda and demonstrates that purified VLPs
are sufficient for correct integration events (13). Gel electrophoresis and electron microscopy have been used to show VLP-mediated insertion of an exogenous linear donor molecule with Ty1
LTR-like termini into both linear and circular target molecules (4). A subset of products analyzed from these insertions
resemble correct integration events. Devine and Boeke (11)
have exploited the integration activity of Ty1 VLPs to insert a
selectable artificial transposon into random sites of target DNA of
unknown sequence as an aid to DNA mapping and sequencing.
Although correct integration has been demonstrated and characterized
for retroviral INs, including human immunodeficiency virus 1 (HIV-1) (8, 9, 20, 22), Rous sarcoma virus (RSV) (28), avian sarcoma virus (22, 24), and avian
myeloblastosis virus (AMV) (17, 27, 36, 37), the ability of
an LTR-retrotransposon IN to carry out correct integration outside the
context of the VLP has not been established. Using a genetic assay
(11), we demonstrate that IN requires no additional
VLP-associated proteins for correct integration of a donor substrate
bearing Ty1 LTR sequences at each end into a supercoiled circular
plasmid target. We have characterized this activity in regard to
efficiency compared to VLPs, target site preference, divalent cation
preference, and utilization of donor molecules containing non-Ty1 LTR
ends. Our survey of mutated ends has shown that while not all sequences are acceptable IN substrates, a variety of mutant substrates undergo correct integration. In addition, Southern hybridization of the reaction reveals products consistent with correct integration events.
 |
MATERIALS AND METHODS |
Purification of Ty1 VLPs and recombinant Ty1 IN.
Ty1 VLPs
were isolated from strain GRY458 using established methods (13,
19). The yeast system for the ectopic expression of Ty1 IN has
been described previously (29). This study required several
IN and VLP preparations, which led to some variability in concentration
and activity. However, experiments involving quantitative comparisons
were carried out with the same IN and VLP preparations.
Purification of donor DNA fragments.
An 864-bp fragment
containing the dihydrofolate reductase gene, which confers resistance
to the antibiotic trimethoprim (TMP), was used as a donor in the
integration assay (11). Half XmnI sites
(GAANN/NNTTC) on each end allowed the introduction of the terminal
5'-AC-3' nucleotides of the Ty1 U3 LTR in the NN position followed by
the two XmnI-specific Ts. The resulting sequence comprises a
U3-like terminus at each end of the donor fragment. This donor fragment, which was purchased from PE Applied Biosystems (Foster City,
Calif.), was cloned into the XmnI site of the plasmid pUC19. This construct was subsequently used as a template for PCR
amplification of donor fragments. Typically, PCRs were carried out for
30 cycles using 2.8 U of Expand high-fidelity DNA polymerase
(Boehringer Mannheim, Indianapolis, Ind.) and 5 ng of template for each
100-µl reaction mixture. Primers and deoxynucleoside triphosphates
were removed from the reactions by Wizard PCR Prep (Promega, Madison, Wis.). The product was restricted with XmnI, which generated
phosphorylated 5' ends. The digested fragment was loaded onto a 1%
low-melting-point agarose (Life Technologies, Rockville, Md.) gel and
resolved at 6.5 V/cm2 for 15 h in the presence of 5 µg of ethidium bromide/ml. Excised DNA fragments were purified by
QiaexII (Qiagen, Valencia, Calif.), and the concentrations were
determined spectrophotometrically. In certain experiments,
amplification using phosphorylated primers allowed inclusion of
additional LTR or mutated sequences and eliminated the requirement for
XmnI digestion and gel purification (see Table 2 for primer
combinations). To avoid untemplated nucleotides at the termini of donor
molecules made by the phosphorylated primer method, Vent DNA polymerase
(New England Biolabs, Beverly, Mass.) was used in the PCR.
The target plasmid, pMC1871, consisted of a pBR322 molecule with the
lacZ gene and a linker of 38 bp inserted into the
-lactamase gene in reverse orientation at a PstI
restriction site (position 3607). This produced a 7,510-bp target
plasmid in which the only functional antibiotic resistance gene
conferred tetracycline resistance. This plasmid was purified by cesium
trifluoroacetate (Amersham-Pharmacia, Piscataway, N.J.) gradient centrifugation.
Integration conditions.
The standard 20-µl reaction
mixture contained 10 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 1 mM dithiothreitol, 5% polyethylene glycol 8000, 200 ng of donor
fragment (0.35 pM), 1 µg of target DNA (0.2 pM), and either Ty1 IN or
Ty1 VLPs. Reaction mixtures were incubated at 30°C for 1 h,
after which 5 µl of stop mix (0.25 M EDTA, 1% sodium dodecyl
sulfate, 5 µg of proteinase K/ml [EM Science, Gibbstown, N.J.]) was
added. The reaction mixtures were then incubated at 65°C for 30 min.
Ammonium acetate was added to a final concentration of 0.33 M, and the
DNA was precipitated by the addition of 2.5 volumes of cold ethanol.
The DNA pellet was washed once in 70% ethanol, dried, and resuspended
in 20 µl of H2O. An aliquot (3 µl for the experiment
shown in Fig. 1, 6 µl for all other experiments) was introduced into
40 µl of HB101 cells at an approximate density of 2 × 1010 cells/ml by electroporation (1.8 kV, 200
resistance, 25 µF capacitance) with electroporation cuvettes having a
gap size of 1 mm (BTX, San Diego, Calif.). After incubation at 37°C
for 1 h, cells were diluted appropriately and plated on L agar
plates containing either 100 µg of TMP/ml and 15 µg of tetracycline
(TET) or TET only. Typically, three dilutions of the cell suspension were each plated in triplicate on TMP-plus-TET plates to select colonies containing integrant plasmids. Two dilutions were each plated
in triplicate on TET-only plates to determine electroporation efficiency. After overnight incubation at 37°C, colonies were counted
and integration efficiency was calculated as the number of TMP-and
TET-resistant colonies divided by the number of TET-only-resistant colonies.
Sequencing.
ABI Prism (PE Applied Biosystems) sequencing
reactions were carried out according to the manufacturer's instructions.
Physical analysis of reaction products.
Reactions for
Southern analysis were carried out as described above except that the
volumes were doubled and contained 460 ng of donor molecule (0.8 pM)
and 5 µg of pUC19 as the target plasmid (2.8 pM). Following the 1-h
incubation period, the reaction was stopped by the introduction of
EDTA, to a final concentration of 63 mM, and 1 µg of proteinase K (EM
Science) per ml in 10 mM Tris-HCl (pH 8.0) with 1 mM EDTA (TE) and
incubated at 37°C for 30 min. The DNA was extracted with
phenol-chloroform-isoamyl alcohol (25:24:1) and ethanol precipitated.
Following precipitation, the pellet was air dried and resuspended in 30 µl of TE. Three microliters of the resuspended DNA was digested with
either StyI or PacI (New England Biolabs).
Undigested controls were incubated in restriction enzyme buffer in the
absence of enzyme. Following incubation at 37°C for 1.5 h, DNA
molecules were resolved electrophoretically on a 1% agarose gel at
0.16 V/cm2 for 14 h. The donor fragment was labeled
with [
-32P]dCTP by Megaprime (Amersham-Pharmacia) and
used as a probe in Southern hybridizations. Phosphorimaging was
performed using a Storm860 and ImageQuant software, version 1.1 (Molecular Dynamics, Sunnyvale, Calif.).
 |
RESULTS |
Comparison of recombinant IN and VLPs and reaction conditions.
Integration experiments were performed to compare recombinant IN and
VLPs in the genetic assay with respect to integration efficiency and
target site preference (Fig. 1). To
estimate the efficiency of recombinant IN and VLPs (Fig. 1A), equal
volumes of protein were added to the reaction mixture
(x axis a). Although the total protein in the
recombinant IN extract (x axis b) was less than that in the
VLP extract (x axis c), the estimated IN concentration in
VLPs (x axis d) was similar to that of recombinant IN. This
estimate was based on an immunoblot comparison of samples of
recombinant IN of a known concentration to VLPs containing an unknown
concentration of IN. ImageQuant analysis indicated that about 1/16 of
total VLP protein consisted of IN.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 1.
Comparison of recombinant Ty1 IN and Ty1 VLPs in the
genetic selection assay. (A) Integration efficiencies with varying
concentrations of recombinant IN or VLP-associated IN, measured as
number of TMP-plus-TET-resistant colonies divided by number of
TET-resistant colonies. The x axes indicate the volume of
protein extract added to the reaction (a), the concentration of Ty1 IN
protein (b), the total protein in the VLP sample (c), and the estimated
concentration of Ty1 IN contained in VLPs (d). Points represent the
mean of three replicate reactions. Vertical bars indicate one standard
deviation from the mean. (B) Target sites mapped by sequence analysis
for recombinant Ty1 IN (outside the circle) and Ty1 VLP (inside the
circle). Only correct integrations are indicated.
|
|
This integration experiment showed VLPs to be approximately fivefold
more active than recombinant IN. One possible explanation for this
difference is that the nucleocapsid component of the VLP, which is
encoded by TYA1, might confer conformational stability to
IN. If so, it is possible that the efficiency of Ty1 IN could be
enhanced by adding TYA1 to the reaction. To test this hypothesis, a
mutant TYB1
plasmid, which lacks the genes encoding
protease, reverse transcriptase, and IN, was overexpressed and VLP
particles consisting of TYA1 only were purified. The addition of up to
3 µg of TYA1 particles to the integration reaction mixture increased the integration efficiency by approximately twofold (Moore and Garfinkel, unpublished results). Since overexpressed TYA1 forms particles which can be pelleted by ultracentrifugation (6), we also determined if IN binds to TYA1 particles in vitro. Although IN
copelleted with TYA1 particles, this association was apparently nonspecific, since the particles also copelleted with bovine serum albumin, HIV-1 IN, and Rac1, a human GTPase (Moore and Garfinkel, unpublished results).
To determine if TMP- plus TET-resistant colonies arose from correct
IN-catalyzed insertion of donor molecules into plasmid targets,
representative colonies were clonally purified and sequenced outward
from both ends of the donor. This sequence showed the donor-target
junction and 5-bp TSD as well as the insertion site on the target.
Plasmids which showed the donor molecule to be flanked by a perfect TSD
and to have both ends joined at the same location in the target
(concerted integration) were classified as correct integration events.
Of the 61 IN-derived plasmids, 51 (84%) were correct integration
events. Fifty-seven of the 66 (86%) VLP-derived plasmids were correct
events. Thus, both INs showed the same proportion of correct
integration events. Incorrect integration events consisted primarily of
imperfectly matched TSDs and/or nonconcerted integration events in
which the two ends of the donor were joined at different sites in the
target (Table 1).
Sequencing data were also used to determine target sites for both VLP
and recombinant IN (Fig. 1B). The insertions appeared randomly
distributed over the nonessential region of the plasmid, and no hot
spots were evident.
To determine if preincubation of donor and IN or VLPs at 0°C enhanced
integration efficiency, reaction mixtures were assembled without the
target plasmid and incubated on ice before adding the target plasmid
and shifting the reaction temperature to 30°C. Preincubation for up
to 5 h showed no increase in TMP- plus TET-resistant colonies for
either IN or VLPs (Moore and Garfinkel, unpublished results).
Divalent cation requirement.
Using an electrophoretic analysis
method for concerted integration, Braiterman and Boeke (4)
have demonstrated that Ty1 VLPs are more active in the presence of
Mg2+ than in the presence of Mn2+. We
quantitated the integration efficiency of recombinant IN in the
presence of Mg2+ or Mn2+ (Fig.
2A) and found that the overall
integration efficiencies were similar. However, sequence analysis of 39 integrant plasmids from Mg2+ colonies and 38 integrant
plasmids from Mn2+ colonies revealed that in this
experiment 74% of the Mg2+-derived products were correct
integration events while only 45% of the Mn2+-derived
products were correct. The most frequent class of aberrant integrations
observed with either cation was integration of each end at separate
sites in the target.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 2.
(A) Effect of the divalent cations Mn2+ and
Mg2+ in the genetic assay. Points represent the mean of two
separate experiments, each having two replicates. Vertical bars
represent one standard deviation from the mean. Ty1 IN concentration is
0.7 µg at each point. (B) Assay for nonspecific endonuclease activity
of Ty1 IN as detected by the conversion of RFI to RFII circles in the
presence of no cation (lanes 2 and 3), Mn2+ (lanes 4 and
5), or Mg2+ (lanes 6 and 7). Lane 1 contained pUC19 only,
in TE. Other reaction mixtures contained pUC19 in reaction buffer with
1.2 µg of Ty1 IN (lanes 3, 5, and 7) or pUC19 in reaction buffer only
(lanes 2, 4, and 6).
|
|
The observation that Mn2+ catalyzes a nonspecific nuclease
activity of HIV-1 IN (15) led us to examine whether Ty1 IN
has a similar activity. Such an activity could influence incorrect target site selection by providing random precleaved insertion sites.
Additionally, adjacent nicked sites could result in a linearized target. Ty1 VLPs have been demonstrated to produce a significant proportion of integration events in which the donor is inserted near
the ends of a linearized target (4). Events of this type might also lead to a higher proportion of incorrect integration events
in reactions in the presence of Mn2+ rather than
Mg2+. To determine whether Ty1 IN exhibited a more
pronounced nuclease activity in the presence of Mn2+
compared to Mg2+, supercoiled pUC19 was incubated in the
presence or absence of 1.2 µg of IN in buffer containing either
Mg2+, Mn2+, or no cation under standard
reaction conditions to monitor conversion of supercoiled circular DNA
(RFI) to nicked circles (RFII) or linear forms. The results showed no
differences in IN-mediated nuclease activity with either cation (Fig.
2B).
Physical analysis of reaction products.
To confirm that
integrants arose from an in vitro IN-mediated reaction rather than a
bacterial cell recombination or DNA repair mechanism, integration
products were visualized by Southern analysis using pUC19 as the
plasmid target and the donor fragment as a hybridization probe (Fig.
3). After terminating the reaction, aliquots were digested with either StyI or PacI,
which recognizes a single site at bp 267 or 132, respectively, in the
donor molecule but no sites in the target plasmid. An additional
aliquot was incubated in restriction enzyme buffer in the absence of
enzyme.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 3.
Southern analysis of integration products. (A) Diagram
of products expected and the fragments resulting from digestion with
either StyI or PacI. Marks on integrated donor
molecules indicate approximate positions of restriction sites. (B)
Electrophoretic analysis of in vitro integration products or with
varying concentrations of IN and either undigested (Lanes 1, 3, 5, 7, and 9) or digested with StyI (Lanes 2, 4, and 6) or
PacI (Lanes 8 and 10). Positions of expected digestion
fragments are indicated by letters corresponding to the indicated
lengths in panel A. Molecular weight standards on the left side of the
figure were derived from the positions of bacteriophage
-HindIII digest and 1 Kb-Plus ladder (Life
Technologies).
|
|
In vitro integration resulted in two types of concerted products in
addition to the nonconcerted events that were detected in this assay
(Fig. 3A). One type of concerted product resulted from a single donor
molecule joined at each end to a unique site in the target
(unimolecular concerted insertion), resulting in an RFII circle.
Another type of concerted integration product which occurred in vitro
arose from the coordinated integration of one end of each of two donor
molecules at the same site in the target. This event resulted in
linearization of the target molecule, with a donor molecule at each end
(bimolecular concerted integration) (37). If all the donor
ends were equally likely to be integrated, four orientations of donor
molecules could occur. Digestion of an integrant population containing
all four orientations with either StyI or PacI
resulted in three products, since two of the orientations were
indistinguishable from each other.
Reactions with Ty1 IN showed two major products in the undigested
samples (Fig. 3B). The slower migrating product was consistent with an
RFII circle. This product was confirmed as a single donor insertion
into a target by using a marker consisting of a partial restriction
digest of pUC19 into which the donor fragment had been cloned (Moore
and Garfinkel, unpublished results). The faster migrating product was
consistent with a linearized, bimolecular concerted integration product
whose predicted size is 4,414 bp. Although both products were digested
with either restriction enzyme, only the bimolecular product gave rise
to the three characteristic smaller fragments shown in Fig. 3A. The
unimolecular insertion was reduced to a linear fragment of 3,550 bp.
The apparent amount of these products increased with increasing IN
concentrations. Products which migrated more slowly than the RFII
likely represent other species of integrants such as multiple donor
insertions or unimolecular half-site events which we have not yet characterized.
Genetic analysis of donor molecules with mutated ends.
Using
the oligoduplex assay for IN activity, we have previously characterized
the ability of molecules with mutated ends to serve as substrates for
Ty1 IN (30). Although an in vitro concerted integration
reaction is not identical to an in vivo transposition event, it does
resemble in vivo integration more closely than the oligoduplex assay.
Wild-type (WT) U3 and mutated donors (Table 2) were used in the genetic selection
assay with both IN and VLPs. Because the U5 sequence has been shown by
a physical assay to be inhibitory for VLP-catalyzed integration
(5), a donor molecule containing a 4-bp WT U3 end and a 4-bp
WT U5 end was tested to determine if the U5 sequence affected
integration efficiency. Vora et al. (35) have reported that
the fifth position of the U5 RSV LTR inhibits activity of AMV IN and
RSV IN, and that when this position is mutated to become a U3-like end,
IN activities increase. To determine if Ty1 LTR sequences beyond the
4-bp termini altered donor utilization, an 8-bp U3/U5 donor was tested.
The TG
CC U3 substitution is of particular importance because this mutation prevents in vivo transposition of an overexpressed Ty1 element
(32). The terminal sequences involving rearrangements such
as TG
GT reversal, TG
GG U3/GT
CC U3, T
A U3/T
A U3 strand flip, and all A-T ends were compared to the results obtained with these
termini in the oligoduplex assay (30), and one substrate with nonphosphorylated ends was tested as a comparison to a similar substrate used previously with VLPs (14).
The results of these experiments indicated that most mutant ends were
recognized to varying degrees by both recombinant IN and VLPs (Table
3). Replacement of one of the 4-bp U3
termini with a 4-bp U5 sequence did not reduce integration efficiency compared to the U3/U3 4-bp WT donor. Inclusion of an additional 4 bp of
LTR sequence at each end (U3/U5 8-bp WT) also did not diminish
integration efficiency, which would be expected if additional U5
sequences were inhibitory.
The TG
CC U3 mutation has been tested in an in vivo transposition
assay (32). This mutant is defective for transposition, although it does undergo cDNA recombination with homologous targets. In
the present study, this mutation coupled with a WT U5 end showed no
reduction in integration efficiency compared to the U3/U3 4-bp WT donor
or to the U3/U5 4-bp WT donor.
The TG
GT end surprisingly demonstrated a deficiency of 120-fold for
IN and 374-fold for VLPs. Few integration events were recovered and
most arose from aberrant insertions. In a previous study using an
oligoduplex assay, we reported that molecules with G-C ends are poor
substrates and that this mutation yields no product (30).
Another donor having a G-C end, the TG
GG U3/GT
CC U3 mutation,
which also fails to give rise to strand transfer products in the
oligoduplex assay, resulted in only a ninefold reduction in integration
efficiency for IN and a fourfold reduction for VLPs.
Because A-T ends are utilized in the oligoduplex assay (30),
two donors were tested in which either the terminal sequences were
flipped (T
A U3/T
A U3) or internal sequences were modified to
create all A-T ends. These substrates showed reduced utilization compared to WT both for efficiency and accuracy of correct integration. The T
A U3/T
A U3 donor was reduced 1.7-fold for IN and 3-fold for
VLP, while the more severe mutant comprised of four A-T pairs showed a
16-fold reduction for IN and a 26-fold reduction for VLPs.
Previous studies indicate that nonphosphorylated substrates yield WT
levels of integration by VLPs (14). Our results with the
U3/U3 WT nonphosphorylated substrate also indicated that 5' phosphorylation is not necessary for IN-mediated integration.
Physical analysis of donor molecules with mutant ends.
Products generated by integration of selected mutant donor
molecules were also examined by Southern analysis using a
32P-labeled donor as previously described (Fig.
4). Although donors carrying mutant ends
gave rise to the same types of products as the WT substrate, the
TG
GT U3 mutant was lower overall in amount of product generated and
was extremely deficient in the RFII product. This result, combined with
the low integration efficiency, suggests that the RFII product is
primarily, if not exclusively, responsible for TMP- plus TET-resistant
colonies recovered in Escherichia coli. The U3/U3 4-bp WT
donor showed the same pattern as observed previously (Fig. 3B).
Interestingly, the TG
CC U3/U5 WT substrate, which is defective for
in vivo transposition, showed product formation similar to that
observed with the U3/U3 WT substrate. The U3/U5 4-bp WT substrate,
while exhibiting both the RFII and linearized products in the
undigested reaction, showed an altered digestion pattern from the U3/U3
WT donor. Although the StyI 3,880-bp fragment and the
PacI 4,150-bp fragment were diminished, the 3,550-bp
fragment of each digest was present as well as the smaller
fragments
StyI, 3,220 bp and PacI, 2,950 bp.
This result suggests that the U3 end was preferentially utilized for
bimolecular integration.

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 4.
Physical assay of reactions carried out with recombinant
Ty1 IN and selected mutant donors. S, digestion with
StyI; P, digestion with PacI. Products
expected are identical to those illustrated in Fig. 3 and are indicated
on the gel.
|
|
 |
DISCUSSION |
Our results demonstrate that purified recombinant Ty1 IN can
integrate an exogenously added linear donor into a supercoiled target
plasmid correctly. Most integration events are concerted and
contain a 5-bp TSD. We have used both a genetic selection and a
physical assay to characterize integration products. The genetic assay
allows recovery of integrant plasmids for further analysis while the
physical assay provides a direct visualization of products without the
intervening step of introducing the products into bacterial cells.
The genetic assay has been used to compare IN and VLPs with respect to
quantitative efficiency, frequency of correct integration events, and
target site selection. A comparison of similar concentrations of
recombinant IN and VLPs shows VLPs to be fivefold more active than
recombinant IN in the genetic assay (Fig. 1A). The interpretation of
this result, however, is not straightforward since it compares activities of Ty1 INs which are in different microenvironments and
which have been purified by different methods. Improvements in protein
purification methods may eventually reduce this difference in activity.
The observation that addition of TYA1 to recombinant IN enhances
integration activity by twofold suggests that TYA1 plays a role in IN
stability but is not entirely competent to perform this function when
added in trans. This is not surprising considering that IN
within the VLP is associated with TYA1 during protein maturation,
whereas recombinant IN is expressed outside the context of the
particle. Additionally, we cannot rule out an as-yet-unidentified
accessory factor which may copurify with VLPs. Sequencing analysis of
plasmids recovered from antibiotic-resistant colonies shows about the
same percentage of correct integrations regardless of whether
recombinant IN or VLP-IN is used. The sequencing analysis (Fig. 1B)
also shows that highly preferred sites for either IN are absent when
purified DNA is used as a target. However, Ty1 transposition in vivo
shows target site selection near genes transcribed by RNA polymerase
III (12). A naked DNA target which lacks chromatin structure
as well as accessory proteins associated with RNA polymerase III
transcription might not be expected to exhibit target site preferences.
We have characterized the divalent cation preference of Ty1 IN (Fig.
2). The presence of a divalent cation, Mn2+ or
Mg2+, is required for catalytic activity of INs (15,
24, 25). Additionally, divalent cations have been shown to
influence structural conformation of IN (2, 39). Although
initial characterization of retroviral INs using the oligoduplex assay
have been reported to require Mn2+ for optimal activity
(10, 15, 24), Engelman and Craigie (15) have
shown that HIV-1 IN can utilize either cation under varied reaction
conditions. Vora et al. (37) and Fitzgerald et al.
(17) characterized the cation requirement of AMV IN and demonstrated that, although Mn2+ efficiently promotes
donor-to-donor insertions and unimolecular half-site insertions into a
circular target, Mg2+ is more efficient for bimolecular
concerted integration into a circular target.
Here, we report that correct concerted integrations catalyzed by Ty1 IN
are more efficient with Mg2+ than with Mn2+.
Although similar numbers of TMP- plus TET-resistant colonies result
when either cation is present in the reaction mixture (Fig. 2A),
sequencing analysis reveals that only 45% of the
Mn2+-derived integrants are correct integrations, compared
with 74% when Mg2+ is present. Engelman and Craigie
(15) have found that HIV-1 IN displays more nonspecific
nuclease activity in the presence of Mn2+ than with
Mg2+. Such an activity might play a role in nonconcerted
integration by creating precleaved insertion sites in the target or by
linearizing the target plasmid. VLP-catalyzed integration yields a
significant class of products in which the donor is integrated near the
end of a linear target (4). We have tested recombinant Ty1
IN for an alteration in nuclease activity in the presence of both
cations under our standard reaction conditions and have observed no
profound difference in the conversion of RFI to RFII circles with
either cation (Fig. 2B). Consequently, the increased proportion of
nonconcerted Mn2+-promoted events does not appear to be due
to nuclease activity on the target plasmid. However, we cannot rule out
that Mn2+ interacts with the target in a different way or
that Mn2+ interacts with other components of the reaction,
permitting less stringent integration.
To visualize IN-catalyzed products directly, we used Southern analysis
with a radiolabeled donor fragment (Fig. 3). This analysis revealed two
predominant products. The faster migrating product is consistent with a
4,414-bp linear fragment resulting from a bimolecular integration (Fig.
3A). The slower migrating product is consistent with an RFII circle
containing one donor fragment per target plasmid, as indicated by an
RFII electrophoretic marker. A comparison of the TG
GT U3/TG
GT U3
donor with the WT U3/U3 donor by using genetic and Southern analyses
suggests that this product represents primarily bimolecular concerted
events. This mutated donor shows a severe deficiency in both
TMP-resistant colony formation and in RFII product in the Southern
analysis. Other mutated donors which are used proficiently in the
genetic assay exhibit near-WT amounts of the RFII product. This result suggests that the RFII product is primarily responsible for colony formation in the genetic assay. Although half-site insertions also
result in RFII products, these events seem unlikely to give rise to
colonies which resemble IN-mediated insertions in the genetic assay.
The possibility also exists that colonies arise from electroporation of
the bimolecular concerted linearized product. Since the donor fragments
initially insert in a concerted manner, sequence analysis of this
fragment might still reveal a target site duplication. However, since
either end of each donor can insert into the target, the sequencing
analysis should have revealed some plasmids which lack a donor-target
junction. If the linear molecules recircularized in the bacterial
cells, sequencing would have revealed donor-donor junctions rather than
donor-target junctions. No aberrant sequences of this type were
detected. Even though we used a recA strain of E. coli as the bacterial host in the genetic assay, we cannot rule
out the possibility that other recombination pathways convert bimolecular linearized products into a form resembling RFIIs. However,
the results shown in Fig. 4 compared with the results of the genetic
assay suggest that this is not a common event. We base this conclusion
particularly on the relative amount of bimolecular linear product
observed with the TG
GT U3/TG
GT U3 substrate compared to the U3/U3
4-bp substrate. Although the amounts of linear product are similar, the
results of the genetic assay show the TG
GT U3/TG
GT U3 substrate
to be reduced by greater than 2 orders of magnitude compared to the
U3/U3 4-bp substrate. If a significant number of recombination events
yielded colonies in the genetic assay, we would have expected to
observe more quantitative similarity between these two substrates.
In a similar assay using exogenous donor and Ty1 VLPs, Braiterman and
Boeke (5) have evaluated several terminal and subterminal donor mutations. Their results show that VLP-mediated integration is
tolerant of a wide range of mutations. In addition, their results suggest that the U3 terminus is preferred and that the U5 terminus is
inhibitory. Although our results for the genetic assay show no
reduction in integration efficiency when one of the U3 termini is
replaced by 4 bp of U5 sequence, Southern analysis indicates that the
U3 end is preferred in bimolecular concerted events. U3 is also the
preferred end for AMV (16, 21, 36, 37), whereas U5 is the
preferred end for HIV-1 (7, 20, 26, 33), human foamy virus
(31), and feline immunodeficiency virus (34). Fitzgerald et al. (17) have suggested that the least
effective terminus is that which is also involved in another element
function and therefore is constrained from evolving into the most
effective substrate for integration. The demonstrated U3-over-U5
preference of Ty1 is consistent with this hypothesis since the U5
terminus is also part of the TYA1 coding sequence.
Vora et al. (35) have shown that the fifth position of the
RSV U5 LTR is responsible for a three- to fivefold preference of U3
ends over U5 ends by RSV IN and AMV IN. Since our U3 WT/U5 4-bp WT
donor showed no reduction in utilization, we also analyzed a U3 WT/U5
WT donor containing 8 bp of each LTR. Additional LTR sequences did not
result in further impairment of U3 WT/U5 WT donor utilization by either
IN or VLP. Rather, the 8-bp LTR donor showed a two- to threefold
enhancement in integration efficiency compared to the 4-bp donor. These
differences in subterminal donor preferences may be attributed to two
differences between the RSV LTR and the Ty1 LTR. The fifth position in
the RSV LTR is the first nonidentical U3/U5 nucleotide, whereas the
third position of the Ty1 LTR is the first nonidentical position.
Additionally, the RSV LTR undergoes IN-mediated 3' dinucleotide
cleavage prior to integration (23), whereas Ty1 LTRs do not
(30). Consequently, the critical fifth position of the RSV
LTR may be analogous to the third position of the Ty1 LTR. If so, then
the important nonidentical nucleotide is included in the 4-bp donor,
and enhanced activity of the 8-bp donor may be due to additional
subterminal LTR sequences. Braiterman and Boeke (5) have
shown that subterminal mutations have a profound effect on VLP-mediated
integration. Wilhelm et al. (38) reported that a subterminal
mutation in the U3 LTR that changes the WT TGG at positions 4 to 6 to
CAT abolishes Ty1 transposition in vivo.
Several of the termini examined in this study have been evaluated in an
oligoduplex assay (30) which showed that Ty1 IN does not
utilize oligoduplexes having G or C termini. The data presented here
are broadly consistent with those results. However, the difference
between G-C termini and A-T termini is not as distinct in the genetic
assay as in the oligoduplex assay. Mutations that exhibit more severe
effects in the oligoduplex assay than in a concerted integration
reaction or in vivo integration have also been reported for
retroviruses (1, 35).
Our results indicate that recombinant Ty1 IN is necessary and
sufficient for catalyzing correct integration in vitro. Both recombinant IN and VLPs show a wide range of tolerance for non-LTR termini of an exogenously added donor, including a terminal mutation which has been shown to be ineffective for in vivo transposition (32). This result suggests that mechanisms which define
specificity for correct ends for transposition may act differently with
exogenous donors than with the endogenous element. Experiments which
utilize the endogenous element in a two-ended integration assay may
indicate whether IN is only promiscuous with exogenous donor or whether an element or host-encoded specificity factor is required to fully reconstitute donor preference in vitro.
 |
ACKNOWLEDGMENTS |
We thank Lori Rinckel for Rac1, Patrick Clark for HIV-1 IN,
Michael Hall for plasmid pMC1871, Duane Grandgenett for helpful discussions, Ellen Frazier for preparation of figures, and Dwight Nissley for critically reading the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Gene Regulation
and Chromosome Biology Laboratory, National Cancer Institute Frederick Cancer Research and Development Center, National Institutes of Health,
Frederick, MD 21702-1201. Phone: (301) 846-5757. Fax: (301) 846-6911. E-mail: moores{at}mail.ncifcrf.gov.
 |
REFERENCES |
| 1.
|
Aiyar, A.,
P. Hindmarsh,
A. M. Skalka, and J. Leis.
1996.
Concerted integration of linear retroviral DNA by the avian sarcoma virus integrase in vitro: dependence on both long terminal repeat termini.
J. Virol.
70:3571-3580[Abstract].
|
| 2.
|
Asante-Appiah, E., and A. M. Skalka.
1997.
Molecular mechanisms in retrovirus DNA integration.
Antivir. Res.
36:139-156[CrossRef][Medline].
|
| 3.
|
Boeke, J., and S. Sandmeyer.
1991.
Yeast transposable elements, p. 193-261.
In
J. Broach, J. Pringle, and E. Jones (ed.), The molecular and cellular biology of the yeast Saccharomyces: genome dynamics, protein synthesis, and energetics, vol. 1. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 4.
|
Braiterman, L. T., and J. D. Boeke.
1994.
In vitro integration of retrotransposon Ty1: a direct physical assay.
Mol. Cell. Biol.
14:5719-5730[Abstract/Free Full Text].
|
| 5.
|
Braiterman, L. T., and J. D. Boeke.
1994.
Ty1 in vitro integration: effects of mutations in cis and in trans.
Mol. Cell. Biol.
14:5731-5740[Abstract/Free Full Text].
|
| 6.
|
Burns, N. R.,
H. R. Saibil,
N. S. White,
J. F. Pardon,
P. A. Timmins,
S. M. Richardson,
B. M. Richards,
S. E. Adams,
S. M. Kingsman, and A. J. Kingsman.
1992.
Symmetry, flexibility and permeability in the structure of yeast retrotransposon virus-like particles.
EMBO J.
11:1155-1164[Medline].
|
| 7.
|
Bushman, F. D., and R. Craigie.
1991.
Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA.
Proc. Natl. Acad. Sci. USA
88:1339-1343[Abstract/Free Full Text].
|
| 8.
|
Carteau, S.,
S. C. Batson,
L. Poljak,
J. F. Mouscadet,
H. de Rocquigny,
J. L. Darlix,
B. P. Roques,
E. Kas, and C. Auclair.
1997.
Human immunodeficiency virus type 1 nucleocapsid protein specifically stimulates Mg2+-dependent DNA integration in vitro.
J. Virol.
71:6225-6229[Abstract].
|
| 9.
|
Carteau, S.,
R. J. Gorelick, and F. D. Bushman.
1999.
Coupled integration of human immunodeficiency virus type 1 cDNA ends by purified integrase in vitro: stimulation by the viral nucleocapsid protein.
J. Virol.
73:6670-6679[Abstract/Free Full Text].
|
| 10.
|
Craigie, R.,
T. Fujiwara, and F. Bushman.
1990.
The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro.
Cell
62:829-837[CrossRef][Medline].
|
| 11.
|
Devine, S. E., and J. D. Boeke.
1994.
Efficient integration of artificial transposons into plasmid targets in vitro: a useful tool for DNA mapping, sequencing and genetic analysis.
Nucleic Acids Res.
22:3765-3772[Abstract/Free Full Text].
|
| 12.
|
Devine, S. E., and J. D. Boeke.
1996.
Integration of the yeast retrotransposon Ty1 is targeted to regions upstream of genes transcribed by RNA polymerase III.
Genes Dev.
10:620-633[Abstract/Free Full Text].
|
| 13.
|
Eichinger, D. J., and J. D. Boeke.
1988.
The DNA intermediate in yeast Ty1 element transposition copurifies with virus-like particles: cell-free Ty1 transposition.
Cell
54:955-966[CrossRef][Medline].
|
| 14.
|
Eichinger, D. J., and J. D. Boeke.
1990.
A specific terminal structure is required for Ty1 transposition.
Genes Dev.
4:324-330[Abstract/Free Full Text].
|
| 15.
|
Engelman, A., and R. Craigie.
1995.
Efficient magnesium-dependent human immunodeficiency virus type 1 integrase activity.
J. Virol.
69:5908-5911[Abstract].
|
| 16.
|
Fitzgerald, M. L.,
A. C. Vora, and D. P. Grandgenett.
1991.
Development of an acid-soluble assay for measuring retrovirus integrase 3'-OH terminal nuclease activity.
Anal. Biochem.
196:19-23[CrossRef][Medline].
|
| 17.
|
Fitzgerald, M. L.,
A. C. Vora,
W. G. Zeh, and D. P. Grandgenett.
1992.
Concerted integration of viral DNA termini by purified avian myeloblastosis virus integrase.
J. Virol.
66:6257-6263[Abstract/Free Full Text].
|
| 18.
|
Garfinkel, D. J.
1992.
Retroelements in microorganisms, p. 107-158.
In
J. A. Levy (ed.), The Retroviridae, vol. 1. Plenum Press, New York, N.Y.
|
| 19.
|
Garfinkel, D. J.,
A. M. Hedge,
S. D. Youngren, and T. D. Copeland.
1991.
Proteolytic processing of pol-TYB proteins from the yeast retrotransposon Ty1.
J. Virol.
65:4573-4581[Abstract/Free Full Text].
|
| 20.
|
Goodarzi, G.,
G. J. Im,
K. Brackmann, and D. Grandgenett.
1995.
Concerted integration of retrovirus-like DNA by human immunodeficiency virus type 1 integrase.
J. Virol.
69:6090-6097[Abstract].
|
| 21.
|
Grandgenett, D. P.,
R. B. Inman,
A. C. Vora, and M. L. Fitzgerald.
1993.
Comparison of DNA binding and integration half-site selection by avian myeloblastosis virus integrase.
J. Virol.
67:2628-2636[Abstract/Free Full Text].
|
| 22.
|
Hindmarsh, P.,
T. Ridky,
R. Reeves,
M. Andrake,
A. M. Skalka, and J. Leis.
1999.
HMG protein family members stimulate human immunodeficiency virus type 1 and avian sarcoma virus concerted DNA integration in vitro.
J. Virol.
73:2994-3003[Abstract/Free Full Text].
|
| 23.
|
Katz, R. A.,
J. P. Mack,
G. Merkel,
J. Kulkosky,
Z. Ge,
J. Leis, and A. M. Skalka.
1992.
Requirement for a conserved serine in both processing and joining activities of retroviral integrase.
Proc. Natl. Acad. Sci. USA
89:6741-6745[Abstract/Free Full Text].
|
| 24.
|
Katz, R. A.,
G. Merkel,
J. Kulkosky,
J. Leis, and A. M. Skalka.
1990.
The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro.
Cell
63:87-95[CrossRef][Medline].
|
| 25.
|
Katzman, M.,
R. A. Katz,
A. M. Skalka, and J. Leis.
1989.
The avian retroviral integration protein cleaves the terminal sequences of linear viral DNA at the in vivo sites of integration.
J. Virol.
63:5319-5327[Abstract/Free Full Text].
|
| 26.
|
LaFemina, R. L.,
P. L. Callahan, and M. G. Cordingley.
1991.
Substrate specificity of recombinant human immunodeficiency virus integrase protein.
J. Virol.
65:5624-5630[Abstract/Free Full Text].
|
| 27.
|
McCord, M.,
R. Chiu,
A. C. Vora, and D. P. Grandgenett.
1999.
Retrovirus DNA termini bound by integrase communicate in trans for full-site integration in vitro.
Virology
259:392-401[CrossRef][Medline].
|
| 28.
|
McCord, M.,
S. J. Stahl,
T. C. Mueser,
C. C. Hyde,
A. C. Vora, and D. P. Grandgenett.
1998.
Purification of recombinant Rous sarcoma virus integrase possessing physical and catalytic properties similar to virion-derived integrase.
Protein Expr. Purif.
14:167-177[CrossRef][Medline].
|
| 29.
|
Moore, S. P., and D. J. Garfinkel.
1994.
Expression and partial purification of enzymatically active recombinant Ty1 integrase in Saccharomyces cerevisiae.
Proc. Natl. Acad. Sci. USA
91:1843-1847[Abstract/Free Full Text].
|
| 30.
|
Moore, S. P.,
M. Powers, and D. J. Garfinkel.
1995.
Substrate specificity of Ty1 integrase.
J. Virol.
69:4683-4692[Abstract].
|
| 31.
|
Pahl, A., and R. M. Flugel.
1993.
Endonucleolytic cleavages and DNA-joining activities of the integration protein of human foamy virus.
J. Virol.
67:5426-5434[Abstract/Free Full Text].
|
| 32.
|
Sharon, G.,
T. J. Burkett, and D. J. Garfinkel.
1994.
Efficient homologous recombination of Ty1 element cDNA when integration is blocked.
Mol. Cell. Biol.
14:6540-6551[Abstract/Free Full Text].
|
| 33.
|
Sherman, P. A.,
M. L. Dickson, and J. A. Fyfe.
1992.
Human immunodeficiency virus type 1 integration protein: DNA sequence requirements for cleaving and joining reactions.
J. Virol.
66:3593-3601[Abstract/Free Full Text].
|
| 34.
|
Vink, C.,
K. H. van der Linden, and R. H. Plasterk.
1994.
Activities of the feline immunodeficiency virus integrase protein produced in Escherichia coli.
J. Virol.
68:1468-1474[Abstract/Free Full Text].
|
| 35.
|
Vora, A. C.,
R. Chiu,
M. McCord,
G. Goodarzi,
S. J. Stahl,
T. C. Mueser,
C. C. Hyde, and D. P. Grandgenett.
1997.
Avian retrovirus U3 and U5 DNA inverted repeats. Role of nonsymmetrical nucleotides in promoting full-site integration by purified virion and bacterial recombinant integrases.
J. Biol. Chem.
272:23938-23945[Abstract/Free Full Text].
|
| 36.
|
Vora, A. C., and D. P. Grandgenett.
1995.
Assembly and catalytic properties of retrovirus integrase-DNA complexes capable of efficiently performing concerted integration.
J. Virol.
69:7483-7488[Abstract].
|
| 37.
|
Vora, A. C.,
M. McCord,
M. L. Fitzgerald,
R. B. Inman, and D. P. Grandgenett.
1994.
Efficient concerted integration of retrovirus-like DNA in vitro by avian myeloblastosis virus integrase.
Nucleic Acids Res.
22:4454-4461[Abstract/Free Full Text].
|
| 38.
|
Wilhelm, M.,
T. Heyman,
M. Boutabout, and F. X. Wilhelm.
1999.
A sequence immediately upstream of the plus-strand primer is essential for plus-strand DNA synthesis of the Saccharomyces cerevisiae Ty1 retrotransposon.
Nucleic Acids Res.
27:4547-4552[Abstract/Free Full Text].
|
| 39.
|
Yi, J.,
E. Asante-Appiah, and A. M. Skalka.
1999.
Divalent cations stimulate preferential recognition of a viral DNA end by HIV-1 integrase.
Biochemistry
38:8458-8468[CrossRef][Medline].
|
Journal of Virology, December 2000, p. 11522-11530, Vol. 74, No. 24
0022-538X/00/$04.00+0